| MDL | - |
|---|---|
| Molecular Weight | 311.31 |
| Molecular Formula | C17H14FN3O2 |
| SMILES | O=C(N)C1=CC=C(C2=CC=NN2C)C=C1OC3=CC=CC=C3F |
RBPJ Inhibitor-1 (RIN1), the first RBPJ inhibitor, blocks the functional interaction of RBPJ with SHARP. RBPJ Inhibitor-1 (RIN1) inhibits NOTCH-dependent tumor cell proliferation [1] .
RIN1 inhibits the proliferation of hematologic cancer cell lines and promoted skeletal muscle diferentiation from C2C12 myoblasts
[1]
.
RIN1 (0.6 µM, corresponding to 3 × IC
50
) decreases the number of MHC+ cells and increased the number of nuclei per cell, indicating that it induces the formation of multinucleated myofbers
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | AD-293 cells were transfected with RBPJ-VP16myc. |
| Concentration: | 2 μM. |
| Incubation Time: | 17 hours. |
| Result: |
Inhibited Hes1-Luciferase activity with an IC
50
of 0.18 µM and E
max
of 82%.
Inhibited NOTCH3 ICD with similar potency and efcacy (0.19 µM and E max =88%). |
Cell Proliferation Assay [1]
| Cell Line: | T-cell acute lymphoblastic leukemia (T-ALL) patients (Jurkat and KOPT-K1) and in the mantle cell lymphoma (MCL) line REC-1. |
| Concentration: | 0.1-10 μM. |
| Incubation Time: | 96 h. |
| Result: |
Inhibited NOTCH-dependent tumor cell proliferation.
Was active in both the cancer cell anti-proliferation and myoblast diferentiation assays. |
Solid
Room temperature in continental US; may vary elsewhere.
| Powder | -20°C | 3 years |
|---|---|---|
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
DMSO : 250 mg/mL ( 803.06 mM ; Need ultrasonic)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.2122 mL | 16.0612 mL | 32.1223 mL |
| 5 mM | 0.6424 mL | 3.2122 mL | 6.4245 mL |
| 10 mM | 0.3212 mL | 1.6061 mL | 3.2122 mL |